{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:12:07Z","timestamp":1790626327926,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016859","name":"Mersana Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016859","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019104","name":"OncoSec Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019402","name":"Puma Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006196","name":"Jet Propulsion Laboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019504","name":"Silverback Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019504","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019799","name":"G1 Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019799","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejca.2022.06.029","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T05:26:28Z","timestamp":1657689988000},"page":"20-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Estimating long-term mortality in women with hormone receptor-positive breast cancer: The \u2018ESTIMATE\u2019 tool"],"prefix":"10.1016","volume":"173","author":[{"given":"Jos\u00e9 P.","family":"Leone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo A.","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0754-3510","authenticated-orcid":false,"given":"Michael J.","family":"Hassett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julieta","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1255-6738","authenticated-orcid":false,"given":"Carlos T.","family":"Vallejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabihah","family":"Tayob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.ejca.2022.06.029_bib1","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2022.06.029_bib2","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1186\/bcr2464","article-title":"PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer","volume":"12","author":"Wishart","year":"2010","journal-title":"Breast Cancer Res"},{"issue":"12","key":"10.1016\/j.ejca.2022.06.029_bib3","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1038\/bjc.2013.671","article-title":"The EndoPredict score provides prognostic information on late distant metastases in ER+\/HER2- breast cancer patients","volume":"109","author":"Dubsky","year":"2013","journal-title":"Br J Cancer"},{"issue":"15","key":"10.1016\/j.ejca.2022.06.029_bib4","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1158\/1078-0432.CCR-13-0804","article-title":"Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2022.06.029_bib5","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S1470-2045(13)70387-5","article-title":"Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population","volume":"14","author":"Sgroi","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2022.06.029_bib6","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1200\/JCO.2014.55.6894","volume":"33","author":"Sestak","year":"2015","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2022.06.029_bib7","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1200\/JCO.2015.62.6630","volume":"34","author":"Wolmark","year":"2016","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2022.06.029_bib8","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2017.76.4258","article-title":"Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 Years of endocrine therapy: CTS5","volume":"36","author":"Dowsett","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2022.06.029_bib9","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1001\/jamaoncol.2018.2574","article-title":"Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial","volume":"4","author":"Sparano","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2022.06.029_bib10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.20.03007","article-title":"Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer","volume":"39","author":"Sparano","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.06.029_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10549-021-06233-4","article-title":"Factors associated with late risks of breast cancer-specific mortality in the SEER registry","volume":"189","author":"Leone","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ejca.2022.06.029_bib12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10549-021-06121-x","article-title":"Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry","volume":"187","author":"Leone","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2022.06.029_bib13","first-page":"1141","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"9","key":"10.1016\/j.ejca.2022.06.029_bib14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJM198608283150906","article-title":"The relation between survival and age at diagnosis in breast cancer","volume":"315","author":"Adami","year":"1986","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2022.06.029_bib15","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1200\/JCO.2007.15.5986","article-title":"Prognostic significance of Nottingham histologic grade in invasive breast carcinoma","volume":"26","author":"Rakha","year":"2008","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2022.06.029_bib16","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/jnci\/94.21.1626","article-title":"Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999","volume":"94","author":"Mariotto","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ejca.2022.06.029_bib17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jnci\/djx239","article-title":"Recent trends in chemotherapy use and oncologists' treatment recommendations for early-stage breast cancer","volume":"110","author":"Kurian","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.ejca.2022.06.029_bib18","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/COC.0000000000000563","article-title":"Prognostic significance of tumor subtypes in women with breast cancer according to stage: a population-based study","volume":"42","author":"Leone","year":"2019","journal-title":"Am J Clin Oncol"},{"issue":"35","key":"10.1016\/j.ejca.2022.06.029_bib19","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.19.00443","article-title":"Incidence of late relapses in patients with HER2-positive breast cancer receiving adjuvant trastuzumab: combined analysis of NCCTG N9831 (alliance) and NRG Oncology\/NSABP B-31","volume":"37","author":"Chumsri","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.06.029_bib20","first-page":"78","article-title":"Older adult participation in cancer clinical trials: a systematic review of barriers and interventions","volume":"71","author":"Sedrak","year":"2021","journal-title":"CA Cancer J Clin"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492200380X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492200380X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:34:36Z","timestamp":1762342476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492200380X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":20,"alternative-id":["S095980492200380X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.06.029","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimating long-term mortality in women with hormone receptor-positive breast cancer: The \u2018ESTIMATE\u2019 tool","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}